NR3C2 and diabetic kidney disease: It is of note that the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial with the non-steroidal mineralocorticoid-receptor-antagonist finerenone on top of standard of care showed cardio- and renoprotection in albuminuric individuals with T2D (65).